Oral delivery product
Latest Pfizer Inc. Patents:
- CDCP1 antibodies and antibody drug conjugates
- Pyrrolo[2,3-d]pyrimidinyl, Pyrrolo[2,3-b]pyrazinyl and Pyrrolo[2,3-d]pyridinyl Acryla-mides
- CRYSTAL-FREE HIGH-CONCENTRATION TESTOSTERONE CYPIONATE FORMULATIONS
- Dosing Regimen of Avelumab for the Treatment of Cancer
- 3-indol substituted derivatives, pharmaceutical compositions and methods for use
Description
Claims
The ornamental design for an oral delivery product, as shown and described.
Referenced Cited
U.S. Patent Documents
| D284114 | June 3, 1986 | Robson |
| D284115 | June 3, 1986 | Robson |
| D448075 | September 18, 2001 | Klaja-McLaughlin |
| D508992 | August 30, 2005 | Kahler |
| D535019 | January 9, 2007 | Stawski |
| D556319 | November 27, 2007 | Chen |
| D569498 | May 20, 2008 | Rasmussen |
| D632386 | February 8, 2011 | Chang |
| D644817 | September 13, 2011 | Hanna |
| D744635 | December 1, 2015 | Chang |
| D748240 | January 26, 2016 | Goode |
| D748241 | January 26, 2016 | Goode |
Patent History
Patent number: D783799
Type: Grant
Filed: Mar 7, 2016
Date of Patent: Apr 11, 2017
Assignee: Pfizer Inc. (New York, NY)
Inventor: Michael A. Goode (Powhatan, VA)
Primary Examiner: Wan Laymon
Assistant Examiner: Clint A Samuel
Application Number: 29/557,191
Type: Grant
Filed: Mar 7, 2016
Date of Patent: Apr 11, 2017
Assignee: Pfizer Inc. (New York, NY)
Inventor: Michael A. Goode (Powhatan, VA)
Primary Examiner: Wan Laymon
Assistant Examiner: Clint A Samuel
Application Number: 29/557,191
Classifications
Current U.S. Class:
Simulative (2) (D24/102)